ID   AGO2_HUMAN              Reviewed;         859 AA.
AC   Q9UKV8; Q8TCZ5; Q8WV58; Q96ID1;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   22-JUL-2015, entry version 142.
DE   RecName: Full=Protein argonaute-2 {ECO:0000255|HAMAP-Rule:MF_03031};
DE            Short=Argonaute2 {ECO:0000255|HAMAP-Rule:MF_03031};
DE            Short=hAgo2;
DE            EC=3.1.26.n2 {ECO:0000255|HAMAP-Rule:MF_03031};
DE   AltName: Full=Argonaute RISC catalytic component 2;
DE   AltName: Full=Eukaryotic translation initiation factor 2C 2 {ECO:0000255|HAMAP-Rule:MF_03031};
DE            Short=eIF-2C 2 {ECO:0000255|HAMAP-Rule:MF_03031};
DE            Short=eIF2C 2 {ECO:0000255|HAMAP-Rule:MF_03031};
DE   AltName: Full=PAZ Piwi domain protein;
DE            Short=PPD;
DE   AltName: Full=Protein slicer {ECO:0000255|HAMAP-Rule:MF_03031};
GN   Name=AGO2; Synonyms=EIF2C2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 239-859 (ISOFORM 1).
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 47-859 (ISOFORM 1).
RX   PubMed=11914277; DOI=10.1101/gad.974702;
RA   Mourelatos Z., Dostie J., Paushkin S., Sharma A., Charroux B.,
RA   Abel L., Rappsilber J., Mann M., Dreyfuss G.;
RT   "miRNPs: a novel class of ribonucleoproteins containing numerous
RT   microRNAs.";
RL   Genes Dev. 16:720-728(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 275-859 (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 483-859 (ISOFORM 1).
RX   PubMed=10534406; DOI=10.1006/geno.1999.5951;
RA   Koesters R., Adams V., Betts D., Moos R., Schmid M., Siermann A.,
RA   Hassam S., Weitz S., Lichter P., Heitz P.U., von Knebel Doeberitz M.,
RA   Briner J.;
RT   "Human eukaryotic initiation factor EIF2C1 gene: cDNA sequence,
RT   genomic organization, localization to chromosomal bands 1p34-p35, and
RT   expression.";
RL   Genomics 61:210-218(1999).
RN   [6]
RP   INTERACTION WITH DICER1.
RX   PubMed=14749716; DOI=10.1038/sj.embor.7400070;
RA   Tahbaz N., Kolb F.A., Zhang H., Jaronczyk K., Filipowicz W.,
RA   Hobman T.C.;
RT   "Characterization of the interactions between mammalian PAZ PIWI
RT   domain proteins and Dicer.";
RL   EMBO Rep. 5:189-194(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15105377; DOI=10.1101/gad.1187904;
RA   Martinez J., Tuschl T.;
RT   "RISC is a 5' phosphomonoester-producing RNA endonuclease.";
RL   Genes Dev. 18:975-980(2004).
RN   [8]
RP   FUNCTION.
RX   PubMed=15260970; DOI=10.1016/j.molcel.2004.07.007;
RA   Meister G., Landthaler M., Patkaniowska A., Dorsett Y., Teng G.,
RA   Tuschl T.;
RT   "Human Argonaute2 mediates RNA cleavage targeted by miRNAs and
RT   siRNAs.";
RL   Mol. Cell 15:185-197(2004).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH GEMIN4.
RX   PubMed=15337849; DOI=10.1261/rna.7131604;
RA   Pillai R.S., Artus C.G., Filipowicz W.;
RT   "Tethering of human Ago proteins to mRNA mimics the miRNA-mediated
RT   repression of protein synthesis.";
RL   RNA 10:1518-1525(2004).
RN   [10]
RP   FUNCTION, ENZYME REGULATION, MUTAGENESIS OF LEU-140; ASP-597; GLN-633;
RP   HIS-634; ASP-669; HIS-682; PHE-704 AND THR-744, AND COFACTOR.
RX   PubMed=15284456; DOI=10.1126/science.1102513;
RA   Liu J., Carmell M.A., Rivas F.V., Marsden C.G., Thomson J.M.,
RA   Song J.-J., Hammond S.M., Joshua-Tor L., Hannon G.J.;
RT   "Argonaute2 is the catalytic engine of mammalian RNAi.";
RL   Science 305:1437-1441(2004).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH DICER1 AND TARBP2.
RX   PubMed=16271387; DOI=10.1016/j.cell.2005.10.022;
RA   Gregory R.I., Chendrimada T.P., Cooch N., Shiekhattar R.;
RT   "Human RISC couples microRNA biogenesis and posttranscriptional gene
RT   silencing.";
RL   Cell 123:631-640(2005).
RN   [12]
RP   FUNCTION, INTERACTION WITH DDX20; DICER1; GEMIN4; MOV10; PRMT5 AND
RP   TNRC6B, AND SUBCELLULAR LOCATION.
RX   PubMed=16289642; DOI=10.1016/j.cub.2005.10.048;
RA   Meister G., Landthaler M., Peters L., Chen P.Y., Urlaub H.,
RA   Luehrmann R., Tuschl T.;
RT   "Identification of novel argonaute-associated proteins.";
RL   Curr. Biol. 15:2149-2155(2005).
RN   [13]
RP   FUNCTION.
RX   PubMed=16142218; DOI=10.1038/sj.embor.7400509;
RA   Haase A.D., Jaskiewicz L., Zhang H., Laine S., Sack R., Gatignol A.,
RA   Filipowicz W.;
RT   "TRBP, a regulator of cellular PKR and HIV-1 virus expression,
RT   interacts with Dicer and functions in RNA silencing.";
RL   EMBO Rep. 6:961-967(2005).
RN   [14]
RP   FUNCTION, INTERACTION WITH DICER1 AND TARBP2, AND MUTAGENESIS OF
RP   ASP-669.
RX   PubMed=16357216; DOI=10.1101/gad.1384005;
RA   Maniataki E., Mourelatos Z.;
RT   "A human, ATP-independent, RISC assembly machine fueled by pre-
RT   miRNA.";
RL   Genes Dev. 19:2979-2990(2005).
RN   [15]
RP   MUTAGENESIS OF LYS-533; GLN-545 AND LYS-570.
RX   PubMed=15800629; DOI=10.1038/nature03514;
RA   Ma J.-B., Yuan Y.-R., Meister G., Pei Y., Tuschl T., Patel D.J.;
RT   "Structural basis for 5'-end-specific recognition of guide RNA by the
RT   A. fulgidus Piwi protein.";
RL   Nature 434:666-670(2005).
RN   [16]
RP   INTERACTION WITH DICER1 AND TARBP2.
RX   PubMed=15973356; DOI=10.1038/nature03868;
RA   Chendrimada T.P., Gregory R.I., Kumaraswamy E., Norman J., Cooch N.,
RA   Nishikura K., Shiekhattar R.;
RT   "TRBP recruits the Dicer complex to Ago2 for microRNA processing and
RT   gene silencing.";
RL   Nature 436:740-744(2005).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15908945; DOI=10.1038/ncb1265;
RA   Sen G.L., Blau H.M.;
RT   "Argonaute 2/RISC resides in sites of mammalian mRNA decay known as
RT   cytoplasmic bodies.";
RL   Nat. Cell Biol. 7:633-636(2005).
RN   [18]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-597;
RP   ASP-669; GLU-673; GLU-683 AND HIS-807.
RX   PubMed=15800637; DOI=10.1038/nsmb918;
RA   Rivas F.V., Tolia N.H., Song J.-J., Aragon J.P., Liu J., Hannon G.J.,
RA   Joshua-Tor L.;
RT   "Purified Argonaute2 and an siRNA form recombinant human RISC.";
RL   Nat. Struct. Mol. Biol. 12:340-349(2005).
RN   [19]
RP   FUNCTION, INTERACTION WITH DCP1A AND XRN1, AND SUBCELLULAR LOCATION.
RX   PubMed=16081698; DOI=10.1126/science.1115079;
RA   Pillai R.S., Bhattacharyya S.N., Artus C.G., Zoller T., Cougot N.,
RA   Basyuk E., Bertrand E., Filipowicz W.;
RT   "Inhibition of translational initiation by Let-7 MicroRNA in human
RT   cells.";
RL   Science 309:1573-1576(2005).
RN   [20]
RP   FUNCTION.
RX   PubMed=16936728; DOI=10.1038/nsmb1140;
RA   Janowski B.A., Huffman K.E., Schwartz J.C., Ram R., Nordsell R.,
RA   Shames D.S., Minna J.D., Corey D.R.;
RT   "Involvement of AGO1 and AGO2 in mammalian transcriptional
RT   silencing.";
RL   Nat. Struct. Mol. Biol. 13:787-792(2006).
RN   [21]
RP   FUNCTION, INTERACTION WITH DDX6 AND AGO1, AND SUBCELLULAR LOCATION.
RX   PubMed=16756390; DOI=10.1371/journal.pbio.0040210;
RA   Chu C.-Y., Rana T.M.;
RT   "Translation repression in human cells by microRNA-induced gene
RT   silencing requires RCK/p54.";
RL   PLoS Biol. 4:E210-E210(2006).
RN   [22]
RP   INTERACTION WITH APOBEC3G.
RX   PubMed=16699599; DOI=10.1371/journal.ppat.0020041;
RA   Wichroski M.J., Robb G.B., Rana T.M.;
RT   "Human retroviral host restriction factors APOBEC3G and APOBEC3F
RT   localize to mRNA processing bodies.";
RL   PLoS Pathog. 2:E41-E41(2006).
RN   [23]
RP   FUNCTION, INTERACTION WITH FXR1, AND SUBCELLULAR LOCATION.
RX   PubMed=17382880; DOI=10.1016/j.cell.2007.01.038;
RA   Vasudevan S., Steitz J.A.;
RT   "AU-rich-element-mediated upregulation of translation by FXR1 and
RT   Argonaute 2.";
RL   Cell 128:1105-1118(2007).
RN   [24]
RP   FUNCTION, AND MUTAGENESIS OF PHE-470 AND PHE-505.
RX   PubMed=17524464; DOI=10.1016/j.cell.2007.05.016;
RA   Kiriakidou M., Tan G.S., Lamprinaki S., De Planell-Saguer M.,
RA   Nelson P.T., Mourelatos Z.;
RT   "An mRNA m7G cap binding-like motif within human Ago2 represses
RT   translation.";
RL   Cell 129:1141-1151(2007).
RN   [25]
RP   FUNCTION, ASSOCIATION WITH POLYSOMES AND MNRP, AND INTERACTION WITH
RP   DDB1; DDX5; DHX30; DHX36; DDX47; ELAVL1; HNRNPF; IGF2BP1; ILF3; MATR3;
RP   PABPC1; RBM4; SART3; UPF1 AND YBX1.
RX   PubMed=17932509; DOI=10.1038/sj.embor.7401088;
RA   Hoeck J., Weinmann L., Ender C., Ruedel S., Kremmer E., Raabe M.,
RA   Urlaub H., Meister G.;
RT   "Proteomic and functional analysis of Argonaute-containing mRNA-
RT   protein complexes in human cells.";
RL   EMBO Rep. 8:1052-1060(2007).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH DHX9.
RX   PubMed=17531811; DOI=10.1016/j.molcel.2007.04.016;
RA   Robb G.B., Rana T.M.;
RT   "RNA helicase A interacts with RISC in human cells and functions in
RT   RISC loading.";
RL   Mol. Cell 26:523-537(2007).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, INTERACTION WITH
RP   DICER1; EIF6; MOV10 AND TARBP2, AND ASSOCIATION WITH THE 60S RIBOSOME.
RX   PubMed=17507929; DOI=10.1038/nature05841;
RA   Chendrimada T.P., Finn K.J., Ji X., Baillat D., Gregory R.I.,
RA   Liebhaber S.A., Pasquinelli A.E., Shiekhattar R.;
RT   "MicroRNA silencing through RISC recruitment of eIF6.";
RL   Nature 447:823-828(2007).
RN   [28]
RP   FUNCTION.
RX   PubMed=18048652; DOI=10.1126/science.1149460;
RA   Vasudevan S., Tong Y., Steitz J.A.;
RT   "Switching from repression to activation: microRNAs can up-regulate
RT   translation.";
RL   Science 318:1931-1934(2007).
RN   [29]
RP   FUNCTION, AND MUTAGENESIS OF ASP-597.
RX   PubMed=18771919; DOI=10.1016/j.cub.2008.07.072;
RA   Wu L., Fan J., Belasco J.G.;
RT   "Importance of translation and nonnucleolytic ago proteins for on-
RT   target RNA interference.";
RL   Curr. Biol. 18:1327-1332(2008).
RN   [30]
RP   FUNCTION, INTERACTION WITH DICER1; P4HA1; P4HB; TNRC6A AND TNRC6B,
RP   SUBCELLULAR LOCATION, HYDROXYLATION AT PRO-700, AND MUTAGENESIS OF
RP   PRO-700.
RX   PubMed=18690212; DOI=10.1038/nature07186;
RA   Qi H.H., Ongusaha P.P., Myllyharju J., Cheng D., Pakkanen O., Shi Y.,
RA   Lee S.W., Peng J., Shi Y.;
RT   "Prolyl 4-hydroxylation regulates Argonaute 2 stability.";
RL   Nature 455:421-424(2008).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH DICER1 AND TARBP2.
RX   PubMed=18178619; DOI=10.1073/pnas.0710869105;
RA   MacRae I.J., Ma E., Zhou M., Robinson C.V., Doudna J.A.;
RT   "In vitro reconstitution of the human RISC-loading complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:512-517(2008).
RN   [32]
RP   FUNCTION, INTERACTION WITH IMP8, AND SUBCELLULAR LOCATION.
RX   PubMed=19167051; DOI=10.1016/j.cell.2008.12.023;
RA   Weinmann L., Hoeck J., Ivacevic T., Ohrt T., Muetze J., Schwille P.,
RA   Kremmer E., Benes V., Urlaub H., Meister G.;
RT   "Importin 8 is a gene silencing factor that targets argonaute proteins
RT   to distinct mRNAs.";
RL   Cell 136:496-507(2009).
RN   [33]
RP   INTERACTION WITH RBM4.
RX   PubMed=19801630; DOI=10.1074/jbc.M109.032946;
RA   Lin J.C., Tarn W.Y.;
RT   "RNA-binding motif protein 4 translocates to cytoplasmic granules and
RT   suppresses translation via argonaute2 during muscle cell
RT   differentiation.";
RL   J. Biol. Chem. 284:34658-34665(2009).
RN   [34]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH LIMD1; WTIP AND AJUBA.
RX   PubMed=20616046; DOI=10.1073/pnas.0914987107;
RA   James V., Zhang Y., Foxler D.E., de Moor C.H., Kong Y.W., Webb T.M.,
RA   Self T.J., Feng Y., Lagos D., Chu C.Y., Rana T.M., Morley S.J.,
RA   Longmore G.D., Bushell M., Sharp T.V.;
RT   "LIM-domain proteins, LIMD1, Ajuba, and WTIP are required for
RT   microRNA-mediated gene silencing.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:12499-12504(2010).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   INTERACTION WITH TNRC6C, AND MUTAGENESIS OF PHE-470 AND PHE-505.
RX   PubMed=21981923; DOI=10.1016/j.molcel.2011.09.007;
RA   Braun J.E., Huntzinger E., Fauser M., Izaurralde E.;
RT   "GW182 proteins directly recruit cytoplasmic deadenylase complexes to
RT   miRNA targets.";
RL   Mol. Cell 44:120-133(2011).
RN   [37]
RP   INTERACTION WITH MOV10.
RX   PubMed=22791714; DOI=10.1074/jbc.M112.354001;
RA   Liu C., Zhang X., Huang F., Yang B., Li J., Liu B., Luo H., Zhang P.,
RA   Zhang H.;
RT   "APOBEC3G inhibits microRNA-mediated repression of translation by
RT   interfering with the interaction between Argonaute-2 and MOV10.";
RL   J. Biol. Chem. 287:29373-29383(2012).
RN   [38]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH APOBEC3A; APOBEC3C;
RP   APOBEC3F; APOBEC3G AND APOBEC3H.
RX   PubMed=22915799; DOI=10.1128/JVI.00595-12;
RA   Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H.;
RT   "HIV-1 replication and APOBEC3 antiviral activity are not regulated by
RT   P bodies.";
RL   J. Virol. 86:11712-11724(2012).
RN   [39]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF GLU-673; PHE-676 AND
RP   HIS-807.
RX   PubMed=23746446; DOI=10.1016/j.celrep.2013.05.033;
RA   Faehnle C.R., Elkayam E., Haase A.D., Hannon G.J., Joshua-Tor L.;
RT   "The making of a slicer: activation of human Argonaute-1.";
RL   Cell Rep. 3:1901-1909(2013).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.69 ANGSTROMS) OF 439-575 IN COMPLEX WITH AMP;
RP   CMP; GMP AND PHOSPHATE.
RX   PubMed=20505670; DOI=10.1038/nature09039;
RA   Frank F., Sonenberg N., Nagar B.;
RT   "Structural basis for 5'-nucleotide base-specific recognition of guide
RT   RNA by human AGO2.";
RL   Nature 465:818-822(2010).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 439-575 IN COMPLEX WITH
RP   7-MGTPG AND ATP.
RX   PubMed=21475248; DOI=10.1038/embor.2011.48;
RA   Frank F., Fabian M.R., Stepinski J., Jemielity J., Darzynkiewicz E.,
RA   Sonenberg N., Nagar B.;
RT   "Structural analysis of 5'-mRNA-cap interactions with the human AGO2
RT   MID domain.";
RL   EMBO Rep. 12:415-420(2011).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) IN COMPLEX WITH MIRNA-20A, AND
RP   GUIDE RNA-BINDING.
RX   PubMed=22682761; DOI=10.1016/j.cell.2012.05.017;
RA   Elkayam E., Kuhn C.D., Tocilj A., Haase A.D., Greene E.M.,
RA   Hannon G.J., Joshua-Tor L.;
RT   "The structure of human argonaute-2 in complex with miR-20a.";
RL   Cell 150:100-110(2012).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) IN COMPLEX WITH RNA AND
RP   L-TRYPTOPHAN, AND GUIDE RNA-BINDING.
RX   PubMed=22539551; DOI=10.1126/science.1221551;
RA   Schirle N.T., MacRae I.J.;
RT   "The crystal structure of human Argonaute2.";
RL   Science 336:1037-1040(2012).
CC   -!- FUNCTION: Required for RNA-mediated gene silencing (RNAi) by the
CC       RNA-induced silencing complex (RISC). The 'minimal RISC' appears
CC       to include AGO2 bound to a short guide RNA such as a microRNA
CC       (miRNA) or short interfering RNA (siRNA). These guide RNAs direct
CC       RISC to complementary mRNAs that are targets for RISC-mediated
CC       gene silencing. The precise mechanism of gene silencing depends on
CC       the degree of complementarity between the miRNA or siRNA and its
CC       target. Binding of RISC to a perfectly complementary mRNA
CC       generally results in silencing due to endonucleolytic cleavage of
CC       the mRNA specifically by AGO2. Binding of RISC to a partially
CC       complementary mRNA results in silencing through inhibition of
CC       translation, and this is independent of endonuclease activity. May
CC       inhibit translation initiation by binding to the 7-methylguanosine
CC       cap, thereby preventing the recruitment of the translation
CC       initiation factor eIF4-E. May also inhibit translation initiation
CC       via interaction with EIF6, which itself binds to the 60S ribosomal
CC       subunit and prevents its association with the 40S ribosomal
CC       subunit. The inhibition of translational initiation leads to the
CC       accumulation of the affected mRNA in cytoplasmic processing bodies
CC       (P-bodies), where mRNA degradation may subsequently occur. In some
CC       cases RISC-mediated translational repression is also observed for
CC       miRNAs that perfectly match the 3' untranslated region (3'-UTR).
CC       Can also up-regulate the translation of specific mRNAs under
CC       certain growth conditions. Binds to the AU element of the 3'-UTR
CC       of the TNF (TNF-alpha) mRNA and up-regulates translation under
CC       conditions of serum starvation. Also required for transcriptional
CC       gene silencing (TGS), in which short RNAs known as antigene RNAs
CC       or agRNAs direct the transcriptional repression of complementary
CC       promoter regions. {ECO:0000269|PubMed:15105377,
CC       ECO:0000269|PubMed:15260970, ECO:0000269|PubMed:15284456,
CC       ECO:0000269|PubMed:15337849, ECO:0000269|PubMed:15800637,
CC       ECO:0000269|PubMed:16081698, ECO:0000269|PubMed:16142218,
CC       ECO:0000269|PubMed:16271387, ECO:0000269|PubMed:16289642,
CC       ECO:0000269|PubMed:16357216, ECO:0000269|PubMed:16756390,
CC       ECO:0000269|PubMed:16936728, ECO:0000269|PubMed:17382880,
CC       ECO:0000269|PubMed:17507929, ECO:0000269|PubMed:17524464,
CC       ECO:0000269|PubMed:17531811, ECO:0000269|PubMed:17932509,
CC       ECO:0000269|PubMed:18048652, ECO:0000269|PubMed:18178619,
CC       ECO:0000269|PubMed:18690212, ECO:0000269|PubMed:18771919,
CC       ECO:0000269|PubMed:19167051, ECO:0000269|PubMed:23746446}.
CC   -!- CATALYTIC ACTIVITY: Endonucleolytic cleavage to 5'-
CC       phosphomonoester. {ECO:0000255|HAMAP-Rule:MF_03031,
CC       ECO:0000269|PubMed:15105377, ECO:0000269|PubMed:23746446}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:15284456};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:15284456};
CC   -!- ENZYME REGULATION: Inhibited by EDTA.
CC       {ECO:0000269|PubMed:15284456}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.1 nM for a synthetic 21-nucleotide single-stranded RNA
CC         {ECO:0000269|PubMed:15105377, ECO:0000269|PubMed:15800637};
CC   -!- SUBUNIT: Interacts with DICER1 through its Piwi domain and with
CC       TARBP2 during assembly of the RNA-induced silencing complex
CC       (RISC). Together, DICER1, AGO2 and TARBP2 constitute the trimeric
CC       RISC loading complex (RLC), or micro-RNA (miRNA) loading complex
CC       (miRLC). Within the RLC/miRLC, DICER1 and TARBP2 are required to
CC       process precursor miRNAs (pre-miRNAs) to mature miRNAs and then
CC       load them onto AGO2. AGO2 bound to the mature miRNA constitutes
CC       the minimal RISC and may subsequently dissociate from DICER1 and
CC       TARBP2. Note however that the term RISC has also been used to
CC       describe the trimeric RLC/miRLC. The formation of RISC complexes
CC       containing siRNAs rather than miRNAs appears to occur
CC       independently of DICER1. Interacts with AGO1. Also interacts with
CC       DDB1, DDX5, DDX6, DDX20, DHX30, DHX36, DDX47, DHX9, EIF6, ELAVL,
CC       FXR1, GEMIN4, HNRNPF, IGF2BP1, ILF3, IMP8, MATR3, MOV10, PABPC1,
CC       PRMT5, P4HA1, P4HB, RBM4, SART3, TNRC6A, TNRC6B, UPF1 and YBX1.
CC       Interacts with the P-body components DCP1A and XRN1. Associates
CC       with polysomes and messenger ribonucleoproteins (mNRPs). Interacts
CC       with RBM4; the interaction is modulated under stress-induced
CC       conditions, occurs under both cell proliferation and
CC       differentiation conditions and in an RNA- and phosphorylation-
CC       independent manner. Interacts with LIMD1, WTIP and AJUBA.
CC       Interacts with TRIM71. Interacts with APOBEC3G in an RNA-dependent
CC       manner. Interacts with APOBEC3A, APOBEC3C, APOBEC3F and APOBEC3H.
CC       {ECO:0000269|PubMed:14749716, ECO:0000269|PubMed:15337849,
CC       ECO:0000269|PubMed:15973356, ECO:0000269|PubMed:16081698,
CC       ECO:0000269|PubMed:16271387, ECO:0000269|PubMed:16289642,
CC       ECO:0000269|PubMed:16357216, ECO:0000269|PubMed:16699599,
CC       ECO:0000269|PubMed:16756390, ECO:0000269|PubMed:17382880,
CC       ECO:0000269|PubMed:17507929, ECO:0000269|PubMed:17531811,
CC       ECO:0000269|PubMed:17932509, ECO:0000269|PubMed:18178619,
CC       ECO:0000269|PubMed:18690212, ECO:0000269|PubMed:19167051,
CC       ECO:0000269|PubMed:19801630, ECO:0000269|PubMed:20505670,
CC       ECO:0000269|PubMed:20616046, ECO:0000269|PubMed:21475248,
CC       ECO:0000269|PubMed:21981923, ECO:0000269|PubMed:22539551,
CC       ECO:0000269|PubMed:22682761, ECO:0000269|PubMed:22791714,
CC       ECO:0000269|PubMed:22915799}.
CC   -!- INTERACTION:
CC       Q9UIV1:CNOT7; NbExp=2; IntAct=EBI-528269, EBI-2105113;
CC       Q96C10:DHX58; NbExp=2; IntAct=EBI-528269, EBI-744193;
CC       Q9UPY3:DICER1; NbExp=14; IntAct=EBI-528269, EBI-395506;
CC       Q13541:EIF4EBP1; NbExp=2; IntAct=EBI-528269, EBI-74090;
CC       Q02790:FKBP4; NbExp=2; IntAct=EBI-528269, EBI-1047444;
CC       P63244:GNB2L1; NbExp=2; IntAct=EBI-528269, EBI-296739;
CC       O15397:IPO8; NbExp=4; IntAct=EBI-528269, EBI-358808;
CC       Q5S007:LRRK2; NbExp=3; IntAct=EBI-528269, EBI-5323863;
CC       Q86UE4:MTDH; NbExp=3; IntAct=EBI-528269, EBI-1046588;
CC       Q15185:PTGES3; NbExp=3; IntAct=EBI-528269, EBI-1049387;
CC       Q15633:TARBP2; NbExp=5; IntAct=EBI-528269, EBI-978581;
CC       Q9UHD2:TBK1; NbExp=2; IntAct=EBI-528269, EBI-356402;
CC       A7MCY6:TBKBP1; NbExp=2; IntAct=EBI-528269, EBI-359969;
CC       Q8NDV7:TNRC6A; NbExp=10; IntAct=EBI-528269, EBI-2269715;
CC       Q9UPQ9:TNRC6B; NbExp=12; IntAct=EBI-528269, EBI-947158;
CC       Q9HCJ0:TNRC6C; NbExp=3; IntAct=EBI-528269, EBI-6507625;
CC       Q9HA38:ZMAT3; NbExp=5; IntAct=EBI-528269, EBI-2548480;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, P-body. Nucleus.
CC       Note=Translational repression of mRNAs results in their
CC       recruitment to P-bodies. Translocation to the nucleus requires
CC       IMP8.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9UKV8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UKV8-2; Sequence=VSP_037001;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The Piwi domain may perform RNA cleavage by a mechanism
CC       similar to that of RNase H. However, while RNase H utilizes a
CC       triad of Asp-Asp-Glu (DDE) for metal ion coordination, this
CC       protein appears to utilize a triad of Asp-Asp-His (DDH).
CC   -!- PTM: Hydroxylated. 4-hydroxylation appears to enhance protein
CC       stability but is not required for miRNA-binding or endonuclease
CC       activity. {ECO:0000255|HAMAP-Rule:MF_03031,
CC       ECO:0000269|PubMed:18690212}.
CC   -!- SIMILARITY: Belongs to the argonaute family. Ago subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_03031}.
CC   -!- SIMILARITY: Contains 1 PAZ domain. {ECO:0000255|HAMAP-
CC       Rule:MF_03031}.
CC   -!- SIMILARITY: Contains 1 Piwi domain. {ECO:0000255|HAMAP-
CC       Rule:MF_03031}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH07633.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAL76093.1; Type=Miscellaneous discrepancy; Note=cDNA contains a duplication of an internal sequence at the 5' end.; Evidence={ECO:0000305};
CC       Sequence=BC125214; Type=Frameshift; Positions=450; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC067931; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107375; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC007633; AAH07633.1; ALT_INIT; mRNA.
DR   EMBL; BC018727; AAH18727.2; -; mRNA.
DR   EMBL; BC125214; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AY077717; AAL76093.1; ALT_SEQ; mRNA.
DR   EMBL; BT007229; AAP35893.1; -; mRNA.
DR   EMBL; AF121255; AAF13034.2; -; mRNA.
DR   CCDS; CCDS55279.1; -. [Q9UKV8-2]
DR   CCDS; CCDS6380.1; -. [Q9UKV8-1]
DR   RefSeq; NP_001158095.1; NM_001164623.1. [Q9UKV8-2]
DR   RefSeq; NP_036286.2; NM_012154.3. [Q9UKV8-1]
DR   UniGene; Hs.743313; -.
DR   PDB; 3LUC; X-ray; 1.69 A; A/B/C=439-575.
DR   PDB; 3LUD; X-ray; 2.10 A; A/B/C=439-575.
DR   PDB; 3LUG; X-ray; 1.85 A; A/B/C=439-575.
DR   PDB; 3LUH; X-ray; 2.00 A; A/B/C=439-575.
DR   PDB; 3LUJ; X-ray; 1.80 A; A/B/C=439-575.
DR   PDB; 3LUK; X-ray; 1.70 A; A/B/C=439-575.
DR   PDB; 3QX8; X-ray; 2.30 A; A/B/C=439-575.
DR   PDB; 3QX9; X-ray; 2.00 A; A/B/C=439-575.
DR   PDB; 4F3T; X-ray; 2.25 A; A=1-859.
DR   PDB; 4OLA; X-ray; 2.30 A; A=1-859.
DR   PDB; 4OLB; X-ray; 2.90 A; A=1-859.
DR   PDB; 4W5N; X-ray; 2.90 A; A=1-859.
DR   PDB; 4W5O; X-ray; 1.80 A; A=1-859.
DR   PDB; 4W5Q; X-ray; 3.10 A; A=1-859.
DR   PDB; 4W5R; X-ray; 2.50 A; A=1-859.
DR   PDB; 4W5T; X-ray; 2.50 A; A=1-859.
DR   PDBsum; 3LUC; -.
DR   PDBsum; 3LUD; -.
DR   PDBsum; 3LUG; -.
DR   PDBsum; 3LUH; -.
DR   PDBsum; 3LUJ; -.
DR   PDBsum; 3LUK; -.
DR   PDBsum; 3QX8; -.
DR   PDBsum; 3QX9; -.
DR   PDBsum; 4F3T; -.
DR   PDBsum; 4OLA; -.
DR   PDBsum; 4OLB; -.
DR   PDBsum; 4W5N; -.
DR   PDBsum; 4W5O; -.
DR   PDBsum; 4W5Q; -.
DR   PDBsum; 4W5R; -.
DR   PDBsum; 4W5T; -.
DR   DisProt; DP00736; -.
DR   ProteinModelPortal; Q9UKV8; -.
DR   SMR; Q9UKV8; 22-859.
DR   BioGrid; 118041; 81.
DR   DIP; DIP-29194N; -.
DR   IntAct; Q9UKV8; 176.
DR   MINT; MINT-1957975; -.
DR   STRING; 9606.ENSP00000220592; -.
DR   PhosphoSite; Q9UKV8; -.
DR   BioMuta; AGO2; -.
DR   DMDM; 229463006; -.
DR   MaxQB; Q9UKV8; -.
DR   PaxDb; Q9UKV8; -.
DR   PRIDE; Q9UKV8; -.
DR   DNASU; 27161; -.
DR   Ensembl; ENST00000220592; ENSP00000220592; ENSG00000123908.
DR   Ensembl; ENST00000519980; ENSP00000430176; ENSG00000123908. [Q9UKV8-2]
DR   GeneID; 27161; -.
DR   KEGG; hsa:27161; -.
DR   UCSC; uc003yvn.3; human. [Q9UKV8-1]
DR   UCSC; uc010meo.3; human. [Q9UKV8-2]
DR   CTD; 27161; -.
DR   GeneCards; GC08M141542; -.
DR   HGNC; HGNC:3263; AGO2.
DR   HPA; CAB019309; -.
DR   MIM; 606229; gene.
DR   neXtProt; NX_Q9UKV8; -.
DR   PharmGKB; PA27694; -.
DR   eggNOG; NOG279895; -.
DR   GeneTree; ENSGT00760000119148; -.
DR   HOGENOM; HOG000116043; -.
DR   InParanoid; Q9UKV8; -.
DR   KO; K11593; -.
DR   OMA; FKHLKYT; -.
DR   OrthoDB; EOG7HHWRC; -.
DR   PhylomeDB; Q9UKV8; -.
DR   TreeFam; TF101510; -.
DR   Reactome; REACT_118560; Small interfering RNA (siRNA) biogenesis.
DR   Reactome; REACT_118568; Pre-NOTCH Transcription and Translation.
DR   Reactome; REACT_118699; Post-transcriptional silencing by small RNAs.
DR   Reactome; REACT_12417; MicroRNA (miRNA) biogenesis.
DR   Reactome; REACT_263982; Ca2+ pathway.
DR   Reactome; REACT_268530; Transcriptional regulation by small RNAs.
DR   Reactome; REACT_75829; PIP3 activates AKT signaling.
DR   EvolutionaryTrace; Q9UKV8; -.
DR   GeneWiki; EIF2C2; -.
DR   GenomeRNAi; 27161; -.
DR   NextBio; 49946; -.
DR   PRO; PR:Q9UKV8; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; Q9UKV8; -.
DR   CleanEx; HS_EIF2C2; -.
DR   ExpressionAtlas; Q9UKV8; baseline and differential.
DR   Genevisible; Q9UKV8; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0000932; C:cytoplasmic mRNA processing body; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0035068; C:micro-ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0005845; C:mRNA cap binding complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IC:BHF-UCL.
DR   GO; GO:0005844; C:polysome; IDA:UniProtKB.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0016442; C:RISC complex; IDA:BHF-UCL.
DR   GO; GO:0070578; C:RISC-loading complex; IDA:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; IMP:BHF-UCL.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:BHF-UCL.
DR   GO; GO:0004521; F:endoribonuclease activity; IDA:BHF-UCL.
DR   GO; GO:0090624; F:endoribonuclease activity, cleaving miRNA-paired mRNA; IDA:BHF-UCL.
DR   GO; GO:0070551; F:endoribonuclease activity, cleaving siRNA-paired mRNA; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0035198; F:miRNA binding; IDA:BHF-UCL.
DR   GO; GO:0003729; F:mRNA binding; IEA:Ensembl.
DR   GO; GO:0044822; F:poly(A) RNA binding; IDA:UniProtKB.
DR   GO; GO:0070883; F:pre-miRNA binding; IDA:BHF-UCL.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:BHF-UCL.
DR   GO; GO:0000340; F:RNA 7-methylguanosine cap binding; IDA:UniProtKB.
DR   GO; GO:0000993; F:RNA polymerase II core binding; IDA:BHF-UCL.
DR   GO; GO:0003727; F:single-stranded RNA binding; IDA:BHF-UCL.
DR   GO; GO:0035197; F:siRNA binding; IDA:UniProtKB.
DR   GO; GO:0003743; F:translation initiation factor activity; NAS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0031047; P:gene silencing by RNA; ISS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0035280; P:miRNA loading onto RISC involved in gene silencing by miRNA; IDA:BHF-UCL.
DR   GO; GO:0010586; P:miRNA metabolic process; IEA:Ensembl.
DR   GO; GO:0035279; P:mRNA cleavage involved in gene silencing by miRNA; IDA:UniProtKB.
DR   GO; GO:0090625; P:mRNA cleavage involved in gene silencing by siRNA; IDA:BHF-UCL.
DR   GO; GO:0035278; P:negative regulation of translation involved in gene silencing by miRNA; IDA:UniProtKB.
DR   GO; GO:0045947; P:negative regulation of translational initiation; IDA:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:1900153; P:positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay; ISS:UniProtKB.
DR   GO; GO:0060213; P:positive regulation of nuclear-transcribed mRNA poly(A) tail shortening; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0016441; P:posttranscriptional gene silencing; TAS:Reactome.
DR   GO; GO:0031054; P:pre-miRNA processing; IDA:UniProtKB.
DR   GO; GO:0035196; P:production of miRNAs involved in gene silencing by miRNA; IDA:BHF-UCL.
DR   GO; GO:0090502; P:RNA phosphodiester bond hydrolysis, endonucleolytic; IDA:GOC.
DR   GO; GO:0010501; P:RNA secondary structure unwinding; IDA:BHF-UCL.
DR   GO; GO:0035087; P:siRNA loading onto RISC involved in RNA interference; IDA:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006412; P:translation; NAS:UniProtKB.
DR   GO; GO:0006413; P:translational initiation; NAS:GOC.
DR   Gene3D; 3.30.420.10; -; 1.
DR   HAMAP; MF_03031; AGO2; 1.
DR   InterPro; IPR028602; AGO2.
DR   InterPro; IPR014811; DUF1785.
DR   InterPro; IPR003100; PAZ_dom.
DR   InterPro; IPR003165; Piwi.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   Pfam; PF08699; DUF1785; 1.
DR   Pfam; PF02170; PAZ; 1.
DR   Pfam; PF02171; Piwi; 1.
DR   SMART; SM00949; PAZ; 1.
DR   SMART; SM00950; Piwi; 1.
DR   SUPFAM; SSF101690; SSF101690; 1.
DR   SUPFAM; SSF53098; SSF53098; 1.
DR   PROSITE; PS50821; PAZ; 1.
DR   PROSITE; PS50822; PIWI; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Endonuclease; Hydrolase; Hydroxylation; Magnesium; Manganese;
KW   Metal-binding; Nitration; Nuclease; Nucleus; Reference proteome;
KW   Repressor; Ribonucleoprotein; RNA-binding;
KW   RNA-mediated gene silencing; Transcription; Transcription regulation;
KW   Translation regulation.
FT   CHAIN         1    859       Protein argonaute-2.
FT                                /FTId=PRO_0000194057.
FT   DOMAIN      235    348       PAZ. {ECO:0000255|HAMAP-Rule:MF_03031}.
FT   DOMAIN      517    818       Piwi. {ECO:0000255|HAMAP-Rule:MF_03031}.
FT   REGION      311    316       Interaction with guide RNA.
FT   REGION      524    566       Interaction with guide RNA.
FT   REGION      587    590       Interaction with GW182 family members.
FT                                {ECO:0000255}.
FT   REGION      650    660       Interaction with GW182 family members.
FT                                {ECO:0000255}.
FT   REGION      709    710       Interaction with guide RNA.
FT   REGION      753    761       Interaction with guide RNA.
FT   REGION      790    812       Interaction with guide RNA.
FT   METAL       597    597       Divalent metal cation. {ECO:0000305}.
FT   METAL       669    669       Divalent metal cation. {ECO:0000305}.
FT   METAL       807    807       Divalent metal cation. {ECO:0000305}.
FT   MOD_RES       2      2       Nitrated tyrosine. {ECO:0000255|HAMAP-
FT                                Rule:MF_03031}.
FT   MOD_RES     700    700       4-hydroxyproline. {ECO:0000255|HAMAP-
FT                                Rule:MF_03031,
FT                                ECO:0000269|PubMed:18690212}.
FT   VAR_SEQ     724    757       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037001.
FT   MUTAGEN     140    140       L->W: No effect.
FT                                {ECO:0000269|PubMed:15284456}.
FT   MUTAGEN     470    470       F->V: No effect on miRNA-binding or
FT                                target mRNA cleavage. Abrogates binding
FT                                to the 7-methylguanosine cap of mRNA and
FT                                prevents inhibition of translation.
FT                                Abolishes interaction with TNRC6C; when
FT                                associated with V-505.
FT                                {ECO:0000269|PubMed:17524464,
FT                                ECO:0000269|PubMed:21981923}.
FT   MUTAGEN     470    470       F->W: No effect on binding to the 7-
FT                                methylguanosine cap of mRNA or inhibition
FT                                of translation.
FT                                {ECO:0000269|PubMed:17524464,
FT                                ECO:0000269|PubMed:21981923}.
FT   MUTAGEN     505    505       F->V: No effect on miRNA-binding or
FT                                target mRNA cleavage. Abrogates binding
FT                                to the 7-methylguanosine cap of mRNA and
FT                                prevents inhibition of translation and
FT                                abolishes interaction with TNRC6C; when
FT                                associated with V-470.
FT                                {ECO:0000269|PubMed:17524464,
FT                                ECO:0000269|PubMed:21981923}.
FT   MUTAGEN     505    505       F->W: No effect on binding to the 7-
FT                                methylguanosine cap of mRNA or inhibition
FT                                of translation.
FT                                {ECO:0000269|PubMed:17524464,
FT                                ECO:0000269|PubMed:21981923}.
FT   MUTAGEN     533    533       K->A: Impairs RNA cleavage.
FT                                {ECO:0000269|PubMed:15800629}.
FT   MUTAGEN     545    545       Q->A: Impairs RNA cleavage.
FT                                {ECO:0000269|PubMed:15800629}.
FT   MUTAGEN     570    570       K->A: Impairs RNA cleavage.
FT                                {ECO:0000269|PubMed:15800629}.
FT   MUTAGEN     597    597       D->A: Abrogates RNA cleavage but does not
FT                                affect binding to siRNA or translational
FT                                repression. {ECO:0000269|PubMed:15284456,
FT                                ECO:0000269|PubMed:15800637,
FT                                ECO:0000269|PubMed:18771919}.
FT   MUTAGEN     633    633       Q->A: No effect.
FT                                {ECO:0000269|PubMed:15284456}.
FT   MUTAGEN     633    633       Q->R: Abrogates RNA cleavage. Binds
FT                                siRNA. {ECO:0000269|PubMed:15284456}.
FT   MUTAGEN     634    634       H->P,A: Abrogates RNA cleavage. Binds
FT                                siRNA. {ECO:0000269|PubMed:15284456}.
FT   MUTAGEN     669    669       D->A: Abrogates RNA cleavage but does not
FT                                affect binding to siRNA.
FT                                {ECO:0000269|PubMed:15284456,
FT                                ECO:0000269|PubMed:15800637,
FT                                ECO:0000269|PubMed:16357216}.
FT   MUTAGEN     673    673       E->A: Impairs RNA cleavage.
FT                                {ECO:0000269|PubMed:15800637,
FT                                ECO:0000269|PubMed:23746446}.
FT   MUTAGEN     673    673       E->G: No effect on RNA cleavage.
FT                                {ECO:0000269|PubMed:15800637,
FT                                ECO:0000269|PubMed:23746446}.
FT   MUTAGEN     676    676       F->A,I,M,R,Y: Impairs RNA cleavage.
FT                                {ECO:0000269|PubMed:23746446}.
FT   MUTAGEN     676    676       F->V: Abrogates RNA cleavage.
FT                                {ECO:0000269|PubMed:23746446}.
FT   MUTAGEN     682    682       H->Y: No effect.
FT                                {ECO:0000269|PubMed:15284456}.
FT   MUTAGEN     683    683       E->G: No effect on RNA cleavage.
FT                                {ECO:0000269|PubMed:15800637}.
FT   MUTAGEN     700    700       P->A: Reduced protein stability.
FT                                {ECO:0000269|PubMed:18690212}.
FT   MUTAGEN     704    704       F->Y: No effect.
FT                                {ECO:0000269|PubMed:15284456}.
FT   MUTAGEN     744    744       T->Y: No effect.
FT                                {ECO:0000269|PubMed:15284456}.
FT   MUTAGEN     807    807       H->A,R: Abrogates RNA cleavage.
FT                                {ECO:0000269|PubMed:15800637,
FT                                ECO:0000269|PubMed:23746446}.
FT   CONFLICT    564    564       C -> W (in Ref. 5; AAF13034).
FT                                {ECO:0000305}.
FT   CONFLICT    589    589       Q -> E (in Ref. 5; AAF13034).
FT                                {ECO:0000305}.
FT   CONFLICT    617    617       S -> R (in Ref. 5; AAF13034).
FT                                {ECO:0000305}.
FT   CONFLICT    637    637       E -> K (in Ref. 3; AAL76093).
FT                                {ECO:0000305}.
FT   STRAND       35     48       {ECO:0000244|PDB:4W5O}.
FT   STRAND       53     63       {ECO:0000244|PDB:4W5O}.
FT   HELIX        68     81       {ECO:0000244|PDB:4W5O}.
FT   TURN         84     87       {ECO:0000244|PDB:4W5O}.
FT   STRAND       96    104       {ECO:0000244|PDB:4W5O}.
FT   TURN        107    110       {ECO:0000244|PDB:4OLA}.
FT   STRAND      113    117       {ECO:0000244|PDB:4W5O}.
FT   STRAND      122    124       {ECO:0000244|PDB:4W5N}.
FT   STRAND      128    139       {ECO:0000244|PDB:4W5O}.
FT   HELIX       140    147       {ECO:0000244|PDB:4W5O}.
FT   STRAND      148    153       {ECO:0000244|PDB:4W5O}.
FT   HELIX       156    173       {ECO:0000244|PDB:4W5O}.
FT   STRAND      174    177       {ECO:0000244|PDB:4W5O}.
FT   STRAND      180    183       {ECO:0000244|PDB:4W5O}.
FT   STRAND      191    193       {ECO:0000244|PDB:4W5O}.
FT   STRAND      196    207       {ECO:0000244|PDB:4W5O}.
FT   STRAND      210    225       {ECO:0000244|PDB:4W5O}.
FT   HELIX       230    238       {ECO:0000244|PDB:4W5O}.
FT   HELIX       243    245       {ECO:0000244|PDB:4W5R}.
FT   HELIX       252    262       {ECO:0000244|PDB:4W5O}.
FT   STRAND      266    268       {ECO:0000244|PDB:4W5O}.
FT   STRAND      278    288       {ECO:0000244|PDB:4W5O}.
FT   TURN        289    291       {ECO:0000244|PDB:4W5O}.
FT   STRAND      293    297       {ECO:0000244|PDB:4F3T}.
FT   STRAND      299    301       {ECO:0000244|PDB:4F3T}.
FT   STRAND      303    307       {ECO:0000244|PDB:4F3T}.
FT   HELIX       308    316       {ECO:0000244|PDB:4W5O}.
FT   STRAND      325    331       {ECO:0000244|PDB:4W5O}.
FT   TURN        333    336       {ECO:0000244|PDB:4F3T}.
FT   STRAND      338    340       {ECO:0000244|PDB:4W5O}.
FT   HELIX       341    343       {ECO:0000244|PDB:4W5O}.
FT   STRAND      344    346       {ECO:0000244|PDB:4F3T}.
FT   STRAND      348    351       {ECO:0000244|PDB:4OLB}.
FT   HELIX       358    368       {ECO:0000244|PDB:4W5O}.
FT   HELIX       372    386       {ECO:0000244|PDB:4W5O}.
FT   HELIX       388    390       {ECO:0000244|PDB:4W5O}.
FT   HELIX       392    396       {ECO:0000244|PDB:4W5O}.
FT   STRAND      406    412       {ECO:0000244|PDB:4W5O}.
FT   TURN        422    425       {ECO:0000244|PDB:4W5O}.
FT   STRAND      450    455       {ECO:0000244|PDB:3LUC}.
FT   TURN        459    461       {ECO:0000244|PDB:3LUC}.
FT   HELIX       464    481       {ECO:0000244|PDB:3LUC}.
FT   STRAND      490    494       {ECO:0000244|PDB:3LUC}.
FT   HELIX       498    500       {ECO:0000244|PDB:3LUC}.
FT   HELIX       501    511       {ECO:0000244|PDB:3LUC}.
FT   STRAND      517    522       {ECO:0000244|PDB:3LUC}.
FT   HELIX       528    537       {ECO:0000244|PDB:3LUC}.
FT   TURN        538    540       {ECO:0000244|PDB:3LUK}.
FT   STRAND      544    548       {ECO:0000244|PDB:3LUC}.
FT   HELIX       549    553       {ECO:0000244|PDB:3LUC}.
FT   HELIX       557    571       {ECO:0000244|PDB:3LUC}.
FT   HELIX       580    582       {ECO:0000244|PDB:4W5O}.
FT   HELIX       585    588       {ECO:0000244|PDB:4W5O}.
FT   STRAND      591    599       {ECO:0000244|PDB:4W5O}.
FT   STRAND      610    617       {ECO:0000244|PDB:4W5O}.
FT   STRAND      619    622       {ECO:0000244|PDB:4W5O}.
FT   STRAND      625    633       {ECO:0000244|PDB:4W5O}.
FT   HELIX       642    657       {ECO:0000244|PDB:4W5O}.
FT   STRAND      662    670       {ECO:0000244|PDB:4W5O}.
FT   HELIX       673    675       {ECO:0000244|PDB:4W5O}.
FT   HELIX       676    694       {ECO:0000244|PDB:4W5O}.
FT   STRAND      701    712       {ECO:0000244|PDB:4W5O}.
FT   STRAND      715    719       {ECO:0000244|PDB:4W5O}.
FT   HELIX       720    722       {ECO:0000244|PDB:4W5O}.
FT   TURN        725    728       {ECO:0000244|PDB:4W5O}.
FT   STRAND      734    736       {ECO:0000244|PDB:4W5O}.
FT   STRAND      738    741       {ECO:0000244|PDB:4W5O}.
FT   STRAND      743    745       {ECO:0000244|PDB:4W5O}.
FT   STRAND      747    751       {ECO:0000244|PDB:4W5O}.
FT   STRAND      757    759       {ECO:0000244|PDB:4OLB}.
FT   STRAND      763    770       {ECO:0000244|PDB:4W5O}.
FT   HELIX       776    786       {ECO:0000244|PDB:4W5O}.
FT   STRAND      793    795       {ECO:0000244|PDB:4F3T}.
FT   HELIX       801    816       {ECO:0000244|PDB:4W5O}.
FT   TURN        817    820       {ECO:0000244|PDB:4W5O}.
FT   HELIX       837    846       {ECO:0000244|PDB:4W5O}.
FT   TURN        850    854       {ECO:0000244|PDB:4W5O}.
SQ   SEQUENCE   859 AA;  97208 MW;  5C8552C43FC81345 CRC64;
     MYSGAGPALA PPAPPPPIQG YAFKPPPRPD FGTSGRTIKL QANFFEMDIP KIDIYHYELD
     IKPEKCPRRV NREIVEHMVQ HFKTQIFGDR KPVFDGRKNL YTAMPLPIGR DKVELEVTLP
     GEGKDRIFKV SIKWVSCVSL QALHDALSGR LPSVPFETIQ ALDVVMRHLP SMRYTPVGRS
     FFTASEGCSN PLGGGREVWF GFHQSVRPSL WKMMLNIDVS ATAFYKAQPV IEFVCEVLDF
     KSIEEQQKPL TDSQRVKFTK EIKGLKVEIT HCGQMKRKYR VCNVTRRPAS HQTFPLQQES
     GQTVECTVAQ YFKDRHKLVL RYPHLPCLQV GQEQKHTYLP LEVCNIVAGQ RCIKKLTDNQ
     TSTMIRATAR SAPDRQEEIS KLMRSASFNT DPYVREFGIM VKDEMTDVTG RVLQPPSILY
     GGRNKAIATP VQGVWDMRNK QFHTGIEIKV WAIACFAPQR QCTEVHLKSF TEQLRKISRD
     AGMPIQGQPC FCKYAQGADS VEPMFRHLKN TYAGLQLVVV ILPGKTPVYA EVKRVGDTVL
     GMATQCVQMK NVQRTTPQTL SNLCLKINVK LGGVNNILLP QGRPPVFQQP VIFLGADVTH
     PPAGDGKKPS IAAVVGSMDA HPNRYCATVR VQQHRQEIIQ DLAAMVRELL IQFYKSTRFK
     PTRIIFYRDG VSEGQFQQVL HHELLAIREA CIKLEKDYQP GITFIVVQKR HHTRLFCTDK
     NERVGKSGNI PAGTTVDTKI THPTEFDFYL CSHAGIQGTS RPSHYHVLWD DNRFSSDELQ
     ILTYQLCHTY VRCTRSVSIP APAYYAHLVA FRARYHLVDK EHDSAEGSHT SGQSNGRDHQ
     ALAKAVQVHQ DTLRTMYFA
//
